Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review

Vaccine

Volumn 27, Issue 52, 2009, Pages 7242-7243

  Postma, Maarten J ^a,b   de Vries, Robin ^a   Roord, John ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Effectiveness; Pertussis booster vaccination

Indexed keywords

PERTUSSIS VACCINE;

ADOLESCENT; ADULT; BOOSTER VACCINATION; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG COST; HEALTH ECONOMICS; HERD IMMUNITY; HUMAN; LETTER; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION, SECONDARY; PERTUSSIS VACCINE; QUALITY-ADJUSTED LIFE YEARS; WHOOPING COUGH;

EID: 70649085932     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.077     Document Type: Letter

References (16)

1. Rodríguez-Cobo I., Chen Y.F., Olowokure B., and Litchfield I. Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review. Vaccine 26 (2008) 6768-6776
2. de Greeff S.C., Schellekens J.F., Mooi F.R., and de Melker H.E. Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003. Ned Tijdschr Geneeskd 149 (2005) 937-943
3. de Greeff S.C., Mooi F.R., Schellekens J.F., and de Melker H.E. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 27 (2008) 218-223
4. Rank C., Quinn H.E., and McIntyre P.B. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 28 (2009) 152-153
5. ® US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years. Pediatr Drugs 8 3 (2006) 189-195
6. Ward J.I., Cherry J.D., Chang S.J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353 (2005) 1555-1563
7. Casey J.R., and Pichichero M.E. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 65 10 (2005) 1367-1389
8. Edmunds W.J., Brisson M., Melegaro A., and Gay N.J. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20 (2002) 1316-1330
9. de Melker H.E., Versteegh F.G., Schellekens J.F., Teunis P.F., and Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 53 (2006) 106-113
10. Welte R., Postma M., Leidl R., and Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 32 (2005) 474-483
11. de Greeff S.C., Lugner A.K., van den Heuvel D.M., Mooi F.R., and de Melker H.E. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine 27 (2009) 1932-1937
12. Lee G.M., Lebaron C., Murphy T.V., Lett S., Schauer S., and Lieu T.A. Pertussis in adolescents and adults: should we vaccinate?. Pediatrics 115 (2005) 1675-1684
13. Caro J.J., Getsios D., El-Hadi W., Payne K., and O'Brien J.A. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 24 5 Suppl (2005) S75-S82
14. Lee G.M., Riffelmann M., and Wirsing von Konig C.H. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 26 (2008) 3673-3679
15. Iskedjian M., Walker J.H., and Hemels M.E. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 22 (2004) 4215-4227
16. Iskedjian M., Walker J.H., De S.G., and Einarson T.R. Economic evaluation of an extended acellular pertussis vaccine program for adolescents in Quebec, Canada. Paediatr Drugs 7 (2005) 123-136